Yuhan Corporation announced on the 11th that the allergy drug candidate 'YH35324' introduced from GI Innovation has demonstrated superior therapeutic efficacy compared to Novartis' 'Xolair'. Yuhan Corporation unveiled the results of the clinical phase 1b study for YH35324 in a paper abstract presented on the 10th (local time) at the American Academy of Allergy, Asthma & Immunology (AAAAI). The company explained that, in a comparison of the effectiveness of YH35324 and Xolair in patients with chronic spontaneous urticaria (CSU), the symptom improvement effect in patients administered YH35324 was found to be superior to that of the Xolair administration group.
Kangstem Biotech announced on the 11th that its stem cell therapy for atopic dermatitis has received approval for a type 1 regenerative medicine provision plan from the specific recognition regeneration medicine committee of the Japanese Ministry of Health, Labour and Welfare. After receiving approval from the committee, type 1 regenerative medicine undergoes final review by the Health Sciences Council under the Ministry of Health, Labour and Welfare. The company plans to proceed with approvals from the Ministry of Health, Labour and Welfare within the second quarter. The company expects to be able to use 'PureStem-AD' as a treatment for atopic patients in medical institutions in Japan within the year.
Enzychem Lifesciences announced on the 11th that it has registered a U.S. substance patent for a new immune modulator, '1,2-diacylglycerol compound', with the U.S. Patent and Trademark Office (USPTO). The 1,2-diacylglycerol compound is a substance that can regulate the overexpression of cytokines (such as IL-4, IL-6) that cause inflammatory responses and chemokines (such as CXCL8) involved in the migration of inflammatory cells. It can be utilized in the prevention and treatment of various immune diseases, including viral infections, acute and chronic inflammatory lung diseases, pneumonia, autoimmune diseases, allergic diseases, and cancer. With this registration, the company has secured rights to this substance in South Korea, the United States, Europe, Japan, China, and India.
Noul announced on the 11th that its next-generation cancer diagnostic technology, 'minimally invasive AI-based cancer diagnostic system', developed in collaboration with Seoul Asan Medical Center, Yonsei Medical Center, and Massachusetts General Hospital (MGH), has been selected as one of the top 10 representative projects for this year in the Interagency Clinical Medical Device Development Project. This system is the world's only fully automated solution, from staining to imaging and AI diagnosis, providing simple and rapid cancer diagnostic tests on-site in a minimally invasive manner. Based on its first commercial product, the AI cervical cancer diagnostic solution (miLab™ CER), the company plans to expand the application range to various types of cancer in the future.
First Biotherapeutics announced on the 11th that it has entered into a strategic partnership with Moffitt Cancer Center, a U.S. cancer research and treatment institution. The two companies plan to jointly develop the next-generation immune anti-cancer drug FB849 while also accelerating global clinical development and conducting translational research and tumor-infiltrating lymphocyte (TIL) cell therapy.
FromBIO announced on the 11th that it has signed a business agreement with Gyeongsangbuk-do, Uiseong-gun, and Yeungnam University Cell Culture Research Institute to jointly develop and supply cell culture media, a core material for advanced biopharmaceuticals. Cell culture media is an essential bio-material that supplies the nutrients necessary for cell culture. With this agreement, FromBIO plans to continue joint development with Professor Choi In-ho's team from Yeungnam University Cell Culture Research Institute, which is an authority on domestic cell culture and media development technology.
Zen Body announced on the 11th that it will supply 150,000 drug testing kits for six types of narcotics to the Military Manpower Administration within the year. The testing kit to be supplied can simultaneously test for six types of narcotics in human urine, including methamphetamine (MET), marijuana (THC), cocaine (COC), morphine (OPI), ketamine (KET), and ecstasy (MDMA). The test results can be verified within 10 minutes, and the kit is easy to use, allowing anyone to operate it without difficulty.
Daewoong Pharmaceutical announced on the 11th that it held a 'Deep Symposium' in collaboration with DNC at the Conrad Hotel in Seoul on the 8th and 9th. Approximately 90 cosmetic surgery practitioners participated in this event, and a hands-on training program was conducted alongside lectures. The Deep (DEEP) Symposium is an educational program designed to consolidate Daewoong Pharmaceutical's medical aesthetics know-how. This year, the theme was 'tailored aesthetics by age group,' focusing on preferred procedures and characteristics for ages ranging from 20s to 60s across a total of five sessions.
Austem announced on the 11th that it will host the 'Orthodontics Contest' for dental technicians nationwide. This competition aims to support clinical research in the orthodontics field and cultivate experts in orthodontic technology, categorized into general orthodontics and transparent orthodontics. Applications will be accepted until the 31st of next month on the dental industry's comprehensive portal site, Denol.
Hyundai ADM Bio announced on the 11th that it has recruited Jo Doo-yeon, head of the clinical trial center at Bundang CHA Hospital, as the head of its medical division. Jo will strengthen clinical trial organization (CRO) operations and oversee the development of cancer stem cell-targeted anti-cancer drugs (CSC-X).
YoungLimWon Soft-Lab announced on the 11th that its Indonesian subsidiary, SystemEver Indonesia (SEI), has signed a supply contract for global sports shoe manufacturing (OEM) and enterprise resource planning (ERP) and manufacturing execution system (MES). The total contract amount is $8.9 million (129 billion won). With this contract, SEI aims to establish an infrastructure for process efficiency and production optimization for its clients, and plans to implement ERP and MES in collaboration with personnel from the headquarters of YoungLimWon Soft-Lab to achieve the digitalization of manufacturing processes and the realization of smart factories.
JW Pharmaceutical announced on the 11th that it conducted a campaign to raise awareness of the importance of anemia treatment in honor of 'World Anemia Awareness Day'. Every year on February 13th is designated as 'World Anemia Awareness Day' by the Society for the Advancement of Blood Management (SABM) and the nonprofit Human Touch Media Foundation, established jointly in 2022. Through this campaign, the company delivered promotional materials along with chocolates to employees working at JW headquarters in Gwacheon, Gyeonggi Province, informing them of the significance of 'World Anemia Awareness Day' and the importance of anemia treatment.
Korea University Anam Hospital announced on the 11th that Professor Kim Soo-jin from the Department of Emergency Medicine has received an award from the Minister of the Korea Disease Control and Prevention Agency. Professor Kim was recognized for her contributions to the establishment of prevention policies for in-and-out of trauma patients as the head of the in-depth investigation project for trauma patients in the emergency room since 2019. The in-depth investigation of trauma patients is a project operated by the Korea Disease Control and Prevention Agency, which tracks the treatment process of trauma patients visiting the emergency room in real-time and collects information. Currently, 23 hospitals nationwide participate in this project, and the collected data is used as foundational material for developing policies to prevent trauma patients.
Seoul National University Hospital announced on the 11th that it has received a donation of 100 million won from KCH Group. KCH Group, which operates in resources, renewable energy, infrastructure, and shipping, has donated a total of 450 million won to Seoul National University Hospital over the past five years. The hospital plans to use the donation received this time for its foundation fund to enhance its educational, research, and clinical capabilities and promote public health.
The Ministry of Health and Welfare announced on the 11th that it has held a 'Suicide Prevention Project and Nationwide Mental Investment Support Project Local Meeting' with deputy heads of cities and provinces and mental health officials. The ministry is implementing the 'Local Government Suicide High-Risk Group Intensive Support Measures' established last December to lower the number of suicide deaths in the country. This meeting was held to provide guidance once again on the intensive support measures for high-risk suicide groups and to encourage the revitalization of the project.